Goodwill and other intangible assets, net

3 Months Ended

Apr. 02, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and other intangible assets, net

Note 6 — Goodwill and other intangible assets, net

The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the three months ended April 2, 2017:



	Vascular North America			Anesthesia North America		Surgical North America		EMEA		Asia		OEM		All Other		Total
	(Dollars in thousands)
Balance as of December 31, 2016	$	345,546		$	141,253	$	250,912	$	290,041	$	138,185	$	4,883	$	105,900	$	1,276,720
Goodwill related to acquisitions	—			—		—		—		—		—		521,396		521,396
Currency translation and other adjustments	(1,590		)	93		—		11,186		5,735		—		1,958		17,382
Balance as of April 2, 2017	$	343,956		$	141,346	$	250,912	$	301,227	$	143,920	$	4,883	$	629,254	$	1,815,498

The following table provides information as of April 2, 2017 and December 31, 2016 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net:



	Gross Carrying Amount				Accumulated Amortization
	April 2, 2017		December 31, 2016		April 2, 2017			December 31, 2016
	(Dollars in thousands)
Customer relationships	$	885,648	$	622,428	$	(248,033	)	$	(239,055	)
In-process research and development	32,689		16,532		—			—
Intellectual property	769,892		519,962		(213,843		)	(203,390		)
Distribution rights	23,185		23,021		(15,673		)	(15,239		)
Trade names	400,406		379,724		(15,357		)	(13,974		)
Non-compete agreements	2,771		2,692		(1,231		)	(1,038		)
	$	2,114,591	$	1,564,359	$	(494,137	)	$	(472,696	)

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details